Form 4 for HUMA Humacyte, Inc.
Accepted 2021-08-27 00:00:00 ET · period of report 2021-08-26 · accession 0001104659-21-110520 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-08-27 | 2021-08-26 | HUMA | Tente William Edward | Chief Regulatory Off | A - Grant | — | +52.5K | 52.5K | New | — |
| DM | 2021-08-27 | 2021-08-26 | HUMA | Tente William Edward | Chief Regulatory Off | A - Grant | — | +310.1K | 91.9K | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-08-26 | A | A | 52,519 | — | 52,519 | D | — | — | (F1) On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each share of Legacy Humacyte stock was exchanged for 0.2626 shares of common stock of Humacyte, Inc. |
| 2 | Derivative | Stock Options (right to buy) | 2021-08-26 | A | A | 1,575 | — | 1,575 | D | $10.28 · 2021-12-14 to 2030-12-14 | 1,575 Common Stock | (F3) As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. (F4) Options to purchase 2,625 shares of Common Stock granted on 12/14/2020, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Accordingly, columns 5, 7, and 9 of Table II report the number of securities equal to three-fifths of the 12/14/2020 option grant. |
| 3 | Derivative | Stock Options (right to buy) | 2021-08-26 | A | A | 91,908 | — | 91,908 | D | $2.56 · — to 2025-12-11 | 91,908 Common Stock | (F3) As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. (F2) Options are fully vested and exercisable. |
| 4 | Derivative | Stock Options (right to buy) | 2021-08-26 | A | A | 6,564 | — | 6,564 | D | $1.15 · — to 2022-12-14 | 6,564 Common Stock | (F3) As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. (F2) Options are fully vested and exercisable. |
| 5 | Derivative | Stock Options (right to buy) | 2021-08-26 | A | A | 118,168 | — | 118,168 | D | $6.54 · — to 2028-04-12 | 118,168 Common Stock | (F3) As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. (F2) Options are fully vested and exercisable. |
| 6 | Derivative | Stock Options (right to buy) | 2021-08-26 | A | A | 91,908 | — | 91,908 | D | $1.19 · — to 2023-11-22 | 91,908 Common Stock | (F3) As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. (F2) Options are fully vested and exercisable. |